Related Experiment Video
Updated: Apr 3, 2026

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
Published on: June 25, 2016
Clinical effects and plasma concentrations of long-term clonazepam monotherapy in previously untreated epileptics
Abstract:
Ninety-three, previously untreated epileptics were subjected to clonazepam monotherapy. The plasma clonazepam concentrations were monitored to achieve optimal therapeutic effects of the drug. Within a mean duration of follow-up of 32 months, 57 (61.3%) of the 93 cases became seizure-free. The drug showed a high efficacy for complete seizure control of more than 80% for both simple partial seizures and primary generalized tonic clonic ones. The mean plasma level of clonazepam giving complete seizure control was 14.7 ng/ml (range: 3.0-34.6 ng/ml) in cases of generalized epilepsy, and 15.6 ng/ml (range: 4.5-42.3 ng/ml) in cases of partial epilepsy. There was a high correlation between the plasma level and the dose, but no correlation between the plasma level and the clinical effect of the drug. The variable therapeutic range and great interindividual differences in the optimal plasma clonazepam level imply that individually tailored regimens are necessary to achieve optimal therapeutic effects of the drug.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...

